BioNxt Solutions Inc. (FRA:BXT)

Germany flag Germany · Delayed Price · Currency is EUR
0.5360
+0.0160 (3.08%)
Last updated: Oct 21, 2025, 5:35 PM CET
3.08%
Market Cap62.55M
Revenue (ttm)13.53K
Net Income (ttm)-3.77M
Shares Outn/a
EPS (ttm)-0.03
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume17,536
Average Volume17,105
Open0.5300
Previous Close0.5200
Day's Range0.5100 - 0.5360
52-Week Range0.1360 - 0.6900
Betan/a
RSI49.26
Earnings DateNov 28, 2025

About BioNxt Solutions

BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis; BNT23002 for the treatment of myasthenia gravis; BNT24002, a sublingual thin film for the treatment of lupus nephritis; BNT24003 for the treatment of rheumatoid arthritis; BNT24004 for longevity and anti-aging; and BNT24004 for the treatment of semaglutide. It also offers diagnostic screening tests; new a... [Read more]

Industry Pharmaceutical Preparations
Founded 2017
Country Canada
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol BXT
Full Company Profile

Financial Performance

In 2024, BioNxt Solutions's revenue was 26,985, a decrease of -92.75% compared to the previous year's 372,247. Losses were -5.31 million, -31.22% less than in 2023.

Financial numbers in CAD Financial Statements

News

BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study

VANCOUVER, BC / ACCESS Newswire / October 21, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in next-generation drug del...

1 day ago - Wallstreet:Online

BioNxt Solutions Provides Update To Annual General Meeting Matters Due To Canadian Postal Strike And IR Activities

VANCOUVER, BC / ACCESS Newswire / October 9, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) wishes to advise its shareholders, due to the Canada Post mail st...

12 days ago - Wallstreet:Online

BioNxt Completes "Fast-Track" US Track One Patent Filing for Sublingual Delivery of Cladribine for the Treatment of Multiple Sclerosis

VANCOUVER, BC / ACCESS Newswire / October 9, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in next-generation drug deli...

13 days ago - Wallstreet:Online

BioNxt Reports Update on Targeted Chemotherapy Drug Delivery Platform

VANCOUVER, BC / ACCESS Newswire / October 2, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a development-stage biopharmaceutical company specializing in ad...

20 days ago - Wallstreet:Online

BioNxt Reports Sublingual Cladribine Multiple Sclerosis Drug Milestones Including Large-Animal Study for Validation and Dosing Optimization

VANCOUVER,BC / ACCESS Newswire / September 29, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience company specializing in innovative drug delivery ...

23 days ago - Wallstreet:Online

BioNxt Solutions Announces Closing of Shares for Debt Settlement

VANCOUVER, BC / ACCESS Newswire / September 19, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:XPHYF)(FSE:4XT) is pleased to announce that, further to its news release of Se...

4 weeks ago - Wallstreet:Online

Terry Lynch Continues as Capital Markets Advisor and BioNxt Retains Investor Relations Professionals

VANCOUVER, BC / ACCESS Newswire / September 19, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that Terry Lynch, CEO of Power Metallic...

4 weeks ago - Wallstreet:Online

BioNxt Advances Semaglutide Oral Dissolvable Film (ODF) Program with Successful Proof-of-Concept and Prototype Development

VANCOUVER, BC / ACCESS Newswire / September 15, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:XPHYF)(FSE:4XT) is pleased to announce the successful completion of proof-of-c...

5 weeks ago - Wallstreet:Online

BioNxt Announces Shares for Debt Settlement

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / September 12, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Compan...

5 weeks ago - Wallstreet:Online

BioNxt Solutions Completes Up-Listing to The OTCQB Market

VANCOUVER, BC / ACCESS Newswire / September 5, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:4XT), is pleased to announce that the common shares of the Company (...

6 weeks ago - Wallstreet:Online

Semaglutide API Delivery Enables Start of Lab-Scale ODF Development at BioNxt

VANCOUVER, BC / ACCESS Newswire / September 2, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:XPHYF)(FSE:4XT) is pleased to announce the receipt of the Semaglutide active...

7 weeks ago - Wallstreet:Online

Promotional Activity Engagements

VANCOUVER, BC / ACCESS Newswire / August 22, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC:BNXTF)(FSE:BXT) reports two investor relations engagements.The Company has engaged ...

2 months ago - Wallstreet:Online

BioNxt Fast-Tracks U.S. Patent for MS Drug and Secures Broad Platform IP Covering Autoimmune Neurology Pipeline

VANCOUVER, BC / ACCESS Newswire / August 20, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in innovative drug delivery...

2 months ago - Wallstreet:Online

BioNxt Solutions Announces Closing of Final Tranche of Oversubscribed Convertible Debenture Unit Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / August 8, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") ...

2 months ago - Wallstreet:Online

BioNxt Solutions Reports Pending Patent Grants in Europe and Eurasia, Strengthening IP Protection for Proprietary Sublingual Cladribine-Based MS Treatment

VANCOUVER, BC / ACCESS Newswire / August 5, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE: BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in innovative drug delivery...

2 months ago - Wallstreet:Online

BioNxt Solutions Announces Closing of First Tranche of Convertible Debenture Unit Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / July 25, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (...

3 months ago - Wallstreet:Online

BioNxt Delivers Positive Results in Patented Cladribine Sublingual Thin-Film Program and Completes Successful Formulation

VANCOUVER, BC / ACCESS Newswire / July 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery s...

3 months ago - Wallstreet:Online

BioNxt Solutions Announces Convertible Debenture Unit Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / July 11, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (...

3 months ago - Wallstreet:Online

BioNxt Solutions Introduces Targeted Chemotherapy Drug Delivery Platform for Precision Oncology

VANCOUVER, BC / ACCESS Newswire / July 8, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a development-stage biopharmaceutical company specializing in ad...

3 months ago - Wallstreet:Online

BioNxt's Sublingual Cladribine Program for MS Ready for Next Phase

VANCOUVER, BC / ACCESS Newswire / July 7, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC:XPHYF)(FSE:4XT), a bioscience innovator specializing in advanced drug delivery systems...

3 months ago - Wallstreet:Online

BioNxt Launches Feasibility Study for Semaglutide Oral Thin Film as Alternative to Injection/Tablets

VANCOUVER, BC / ACCESS Newswire / June 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC:BNXTF)(FSE:BXT), is pleased to announce the launch of a feasibility study for the dev...

4 months ago - Wallstreet:Online

BioNxt Solutions Reports Formal Notice from the European Patent Office of Intention to Grant Patent

VANCOUVER, BC / ACCESS Newswire / May 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery sy...

5 months ago - Wallstreet:Online

Bionxt Solutions Provides Bi-Weekly MCTO Status Report

VANCOUVER, BC / ACCESS Newswire / May 15, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:XPHYF)(FSE:4XT), announces that, further to its news release dated May 1, 2025 (t...

5 months ago - Wallstreet:Online

BioNxt Reports Expanded Research, Development and Commercialization Capability with Centralized Munich Laboratory

VANCOUVER, BC / ACCESS Newswire / May 13, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery syst...

5 months ago - Wallstreet:Online

BioNxt Solutions Reports Expanded Patent Protection from the Eurasian Patent Organization

VANCOUVER, BC / ACCESS Newswire / May 5, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery sys...

6 months ago - Wallstreet:Online